Recently, one study showed that treating breast cancer with Paclitaxel can increase macrophage chemotactic factors such as CCL8, IL-34, CSF-1, and CSF-1 receptors in vivo [49] to enhance TAM migration. Here, CSF1R is linked to breast cancer.